- Home
- EPAM vs ORKA Comparison
EPAM vs ORKA Comparison
Compare EPAM & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPAM | ORKA |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.5B |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | EPAM | ORKA |
|---|---|---|
| Price | $87.58 | $83.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $196.21 | $92.50 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $1,450,448,000.00 | N/A |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $7.17 | N/A |
| P/E Ratio | $56.11 | ★ N/A |
| Revenue Growth | ★ 25.02 | N/A |
| 52 Week Low | $73.06 | $12.48 |
| 52 Week High | $222.53 | $97.78 |
Technical Indicators
Market Signals| Indicator | EPAM | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 58.97 |
| Support Level | $73.06 | $27.81 |
| Resistance Level | $109.06 | $91.00 |
| Average True Range (ATR) | 4.37 | 5.31 |
| MACD | 0.88 | 1.34 |
| Stochastic Oscillator | 61.85 | 54.97 |
Price Performance
Historical ComparisonAbout EPAM EPAM Systems Inc.
EPAM Systems is a global IT services firm with a focus on platform engineering, software development, and consulting services. The company used to host large engineer bases in Ukraine, Belarus, and Russia, but it now delivers from various locations across different continents. EPAM's largest market is North America, which represents approximately 60% of revenue.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.